Response to R. Waldman et al.: ‘Does IL‐4 inhibition play a role in dupilumab‐associated conjunctivitis?’

por Ardeleanu, M., Shumel, B., Rossi, A.B., Graham, N.M.H.
Publicado 2020

Incisional negative pressure wound therapy dressings (iNPWTd) in routine primary hip and knee arthroplasties: A randomised controlled trial

por Karlakki, S. L., Hamad, A. K., Whittall, C., Graham, N. M., Banerjee, R. D., Kuiper, J. H.
Publicado 2016

Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis

por Yosipovitch, G., Reaney, M., Mastey, V., Eckert, L., Abbé, A., Nelson, L., Clark, M., Williams, N., Chen, Z., Ardeleanu, M., Akinlade, B., Graham, N.M.H., Pirozzi, G., Staudinger, H., Plaum, S., Radin, A., Gadkari, A.
Publicado 2019

Laboratory safety of dupilumab in moderate‐to‐severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)

por Wollenberg, A., Beck, L.A., Blauvelt, A., Simpson, E.L., Chen, Z., Chen, Q., Shumel, B., Khokhar, F.A., Hultsch, T., Rizova, E., Rossi, A.B., Graham, N.M.H., Pirozzi, G., Lu, Y., Ardeleanu, M.
Publicado 2019

Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a...

por Silverberg, J.I., Simpson, E.L., Ardeleanu, M., Thaçi, D., Barbarot, S., Bagel, J., Chen, Z., Eckert, L., Chao, J., Korotzer, A., Rizova, E., Rossi, A.B., Lu, Y., Graham, N.M.H., Hultsch, T., Pirozzi, G., Akinlade, B.
Publicado 2019

Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open‐label phase IIa stud...

por Cork, M.J., Thaçi, D., Eichenfield, L.F., Arkwright, P.D., Sun, X., Chen, Z., Akinlade, B., Boklage, S., Guillemin, I., Kosloski, M.P., Kamal, M.A., O’Malley, J.T., Patel, N., Graham, N.M.H., Bansal, A.
Publicado 2020

A phase 2, open‐label study of single‐dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy

por Paller, A.S., Siegfried, E.C., Simpson, E.L., Cork, M.J., Lockshin, B., Kosloski, M.P., Kamal, M.A., Davis, J.D., Sun, X., Pirozzi, G., Graham, N.M.H., Gadkari, A., Eckert, L., Ruddy, M., Bansal, A.
Publicado 2020

Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase IIa open‐label trial and subsequent phase III open‐label extension

por Cork, M.J., Thaçi, D., Eichenfield, L.F., Arkwright, P.D., Hultsch, T., Davis, J.D., Zhang, Y., Zhu, X., Chen, Z., Li, M., Ardeleanu, M., Teper, A., Akinlade, B., Gadkari, A., Eckert, L., Kamal, M.A., Ruddy, M., Graham, N.M.H., Pirozzi, G., Stahl, N., DiCioccio, A.T., Bansal, A.
Publicado 2019

Conjunctivitis in dupilumab clinical trials

por Akinlade, B., Guttman‐Yassky, E., de Bruin‐Weller, M., Simpson, E.L., Blauvelt, A., Cork, M.J., Prens, E., Asbell, P., Akpek, E., Corren, J., Bachert, C., Hirano, I., Weyne, J., Korotzer, A., Chen, Z., Hultsch, T., Zhu, X., Davis, J.D., Mannent, L., Hamilton, J.D., Teper, A., Staudinger, H., Rizova, E., Pirozzi, G., Graham, N.M.H., Shumel, B., Ardeleanu, M., Wollenberg, A.
Publicado 2019